Free Newsletter
Daiichi chief 'confident' in Ranbaxy's future
Free newsletter via e-mail
Tools
The head of Daiichi Sankyo, the Japanese pharmaceutical company, expressed his regrets over the high cost of the purchase last year of Ranbaxy, the Indian generic drugs group, while defending the future benefits of the deal. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: